通化东宝：门冬胰岛素注射液获印度尼西亚药品注册证书

Core Viewpoint - The company has received approval from the Indonesian Food and Drug Authority for the registration of its rapid-acting insulin aspart injection, which will enhance its international product line and competitiveness in emerging markets [1] Group 1 - The company has been granted a drug registration certificate for insulin aspart injection (registration number: DKI2570600143A1) by the Indonesian Republic Food and Drug Authority [1] - Insulin aspart is a rapid-acting insulin analog that begins to take effect 10-20 minutes after subcutaneous injection and lasts for 3-5 hours, primarily used for controlling postprandial blood sugar [1] - This approval will help the company enrich its international product offerings, improve brand image, and expand its international business [1]